PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. - Wikidata - wikimedia - TriplyDB

PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.

PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.

http://www.wikidata.org/entity/Q36393206

about

Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis PI3K mutations in breast cancer: prognostic and therapeutic implications PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis.Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapa PIK3R1 underexpression is an independent prognostic marker in breast cancer.Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing.Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948.In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.Association of estrogen receptor-α A908G (K303R) mutation with breast cancer risk.Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases.TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis.Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis.Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy.Metabolomic characterisation of the effects of oncogenic PIK3CA transformation in a breast epithelial cell line.Gene of the month: PIK3CA.Resistance to Targeted Therapies in Breast Cancer.Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.

P2860

Q26751511-3C1D4ABC-DCA7-4EAC-8AB2-D299E9BFBA58 Q26776018-BE85ECE0-460A-4A71-B0E7-23A2431D8389 Q28081992-0D8B8955-BE27-48B9-A37D-5E0BB47BE476 Q28247338-219381B4-FFEA-45E6-9F86-57EC2520A229 Q30823432-BC3FABFF-3293-49BA-BAE5-2EFF30ED337D Q33674656-D95BE4B3-0980-4E01-953D-CB2DD9BE5CF1 Q33716499-49B5C504-82DA-43F7-9D81-BDB4DF68BA75 Q33756991-6A0C2AC2-69B6-458C-88E1-1E0D11DC4DC4 Q33921084-FEF74D51-68D7-4CBC-8931-7613CC7709B9 Q34103963-F8DED2E0-71C6-49AF-9FD7-4BA8266FD06D Q34112879-A7812110-C4CE-4F0B-87FA-ACF6B3A22F83 Q34296114-81AA5401-2E6D-4693-9CB5-B42B4914F9E8 Q34478129-711D24CE-5A14-46F2-B98B-05B96E364B52 Q34486201-F3013DD9-AC6F-4DF3-9D1D-655285E93048 Q34542434-8C5764F3-4643-4B55-B9B5-89141900E19B Q35100056-C3775B4F-72A8-4E52-9252-3128024DE135 Q35178113-C678CC7E-8F37-462D-8ED6-6ECB3067F813 Q35801713-AFF38950-2304-4012-B3FE-62732683643A Q35833567-15F97BD7-4ECA-4A0E-B9E5-DA45AAF2BED1 Q35846874-1ACFA1E4-A2A6-4C9B-A4BD-90FA88C36AF2 Q35872476-0ED30075-7C3B-49C6-8146-A3E2F7BA581F Q36093388-DE98B758-4551-4DAE-8CCF-76B43B197ECA Q36109108-5B114311-B1C6-4187-9929-4AF197766B4C Q36228558-363B3538-3226-49F6-9513-7FD2B3DD651C Q36449789-222436AE-4ABF-4981-B20A-320823638E23 Q36467458-04E86EC1-44C0-4BC5-AC84-20E4A3A3E16B Q36575502-81EBCC77-C536-419F-927E-72A0847690BC Q36976208-42BE4D09-A50C-4BEC-901D-B76D8C27FBAB Q37205007-2D75FF73-D577-46B6-B120-8B7D6F332A3F Q37362747-885E8F09-F7D2-4455-A4C9-883707DB34FB Q37380424-D79BBB93-EFF7-452F-ABDF-E6CAFE483925 Q37690039-CF8AA3D5-F866-4F78-B50D-F51955D705E1 Q37702222-F5A60B2F-D480-4B9E-827D-9270DE783989 Q37708928-9C7EAF19-7600-4E9D-9CE1-6BE012C616BC Q37709099-B5A97EF3-A4AB-4183-9DBA-2D5FAA691083 Q37741425-167819BC-494A-43C4-BBCB-2FD28BDA569D Q37743312-F71FFCD6-1CB6-4D0D-8E4A-0EB849EC1135 Q38358055-C514C266-122E-4076-9236-DA1EF16350A5 Q38748114-C4621487-C33C-4FC7-9193-EFEB6C6DE298 Q38752466-9C8B0E31-71FE-47AC-BECF-A45547CE9CE6

P2860

PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.

http://www.wikidata.org/entity/Q36393206

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

PIK3CA mutation impact on surv ...... PR and ERBB2-based subgroups.

@ast

PIK3CA mutation impact on surv ...... PR and ERBB2-based subgroups.

@en

type

label

PIK3CA mutation impact on surv ...... PR and ERBB2-based subgroups.

@ast

PIK3CA mutation impact on surv ...... PR and ERBB2-based subgroups.

@en

prefLabel

PIK3CA mutation impact on surv ...... PR and ERBB2-based subgroups.

@ast

PIK3CA mutation impact on surv ...... PR and ERBB2-based subgroups.

@en

P1433

Q36393206-077D20E3-1FC4-49B8-A436-E6321C09C907

P1476

Q36393206-722448E0-1862-42DD-8F6D-9D6861E5D20C

P2093

Q36393206-0EAA0D57-F18C-4E7A-A15D-C4BBB85BC6EA

Q36393206-91D86977-364D-47F5-AFC9-9D5BF7EFFF10

Q36393206-A9F79B6D-1B28-4F9F-9F83-385C8C70226E

Q36393206-F3FFF32E-11AD-436F-A505-BFD34A015C43

Q36393206-F7044A3A-C42A-46D1-A6E4-278DBEC09B30

P2860

Q36393206-044CF9B7-0232-48CA-9E0E-E7C8FCFF6B2F

Q36393206-1E6C2AE1-DD91-44D8-96B9-D8456AB9A5E2

Q36393206-245E0D9B-F140-4E33-AD97-4E48F8932042

Q36393206-37185C28-BAE3-49C9-9229-232A9B2DACDD

Q36393206-38D7C0C3-D107-4210-9F8B-EC717D737A4E

Q36393206-39F604AD-D52E-4CDC-B797-1A4ED767DA84

Q36393206-41CBDC31-252E-4188-A340-47DEE5961A52

Q36393206-63686D12-2B05-422D-A74D-934C55DCFE64

Q36393206-6E20375E-AFE6-4644-8709-8B50CFCD3C58

Q36393206-71B50056-BF4F-4702-9D99-9F608801F88C

P2888

Q36393206-D7B6213B-75D7-4EFB-A33E-89A39DFDBA9A

P304

Q36393206-2867D9D9-B319-46BE-B2F6-F3819C642333

P31

Q36393206-3E2C8505-89F5-4D13-AAD0-F82F557F876B

P356

Q36393206-74D04A11-BDC2-44BE-8C67-E9DC5257AE0F

P433

Q36393206-0847F71E-7F5B-46EF-9089-6324096AD6CF

P478

Q36393206-81D08026-3B37-4B85-BE59-9654B4A3DEB0

P50

Q36393206-0BC2C685-6E8F-419E-9FA4-30514D2A2523

Q36393206-57FBD1A0-2520-449B-AFD6-1B4307CA9925

Q36393206-96D0BD20-97DD-46D9-A706-5B13A51A7721

Q36393206-B7FA87A5-F26A-48F3-B47B-459CCFC746C3

P577

Q36393206-69CBCFC0-16FF-4020-9C36-DB7072D99501

P5875

Q36393206-A62D8795-8527-4C29-9909-38BBF999455F

P6179

Q36393206-B539322F-1706-44E5-96DC-531BF4F8F069

P698

Q36393206-B7E7A0B8-37FA-44C1-8B69-DA14796693F7

P921

Q36393206-CB5BF343-A746-4EB6-A25E-72C4A0388550

P932

Q36393206-2F90ECD5-D595-471C-89E9-7B381D47AD8C

P356

P1433

Breast Cancer Research

P1476

PIK3CA mutation impact on surv ...... PR and ERBB2-based subgroups.

@en

P2093

Aurélie Susini

http://www.w3.org/2001/XMLSchema#string

Catherine Andrieu

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Fourme

http://www.w3.org/2001/XMLSchema#string

Keltouma Driouch

http://www.w3.org/2001/XMLSchema#string

Magdalena Cizkova

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Nonparametric Estimation from Incomplete Observations

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.

PIK3CA mutations in in situ and invasive breast carcinomas.

The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.

P2888

P304

R28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR3113

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Géraldine Cizeron-Clairac

Rosette Lidereau

P577

2012-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221829077

http://www.w3.org/2001/XMLSchema#string

P6179

1046903391

http://www.w3.org/2001/XMLSchema#string

P698

22330809

http://www.w3.org/2001/XMLSchema#string

P921

P932

3496146

http://www.w3.org/2001/XMLSchema#string